S100A2 and cervical carcinoma: As less than 60% of cervical cancers express PD-L1 [4], the mechanism of S100A2 upregulation driving PD-L1 expression and leading to immunotherapy resistance necessitates further exploration, specifically whether S100A2 is associated with patient outcomes linked to PD-L1 expression.